A phase II multicenter, double-blind, placebo-controlled, trial of VLTS-589 [del-1 gene therapy] in subjects with intermittent claudication secondary to peripheral arterial disease

Trial Profile

A phase II multicenter, double-blind, placebo-controlled, trial of VLTS-589 [del-1 gene therapy] in subjects with intermittent claudication secondary to peripheral arterial disease

Completed
Phase of Trial: Phase II

Latest Information Update: 09 Mar 2010

At a glance

  • Drugs Del-1 gene therapy (Primary)
  • Indications Intermittent claudication
  • Focus Therapeutic Use
  • Sponsors Urigen Pharmaceuticals
  • Most Recent Events

    • 02 Feb 2006 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top